Matthew Kowgier

3.9k total citations · 1 hit paper
44 papers, 1.9k citations indexed

About

Matthew Kowgier is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Matthew Kowgier has authored 44 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 10 papers in Epidemiology and 9 papers in Oncology. Recurrent topics in Matthew Kowgier's work include Hepatitis C virus research (12 papers), Ovarian cancer diagnosis and treatment (7 papers) and Liver Disease Diagnosis and Treatment (6 papers). Matthew Kowgier is often cited by papers focused on Hepatitis C virus research (12 papers), Ovarian cancer diagnosis and treatment (7 papers) and Liver Disease Diagnosis and Treatment (6 papers). Matthew Kowgier collaborates with scholars based in Canada, United States and Netherlands. Matthew Kowgier's co-authors include Lei Yu, David A. Bennett, Andrew Lim, Aron S. Buchman, Jordan J. Feld, George Tomlinson, David Wong, Julie A. Schneider, Harry L.A. Janssen and Morris Sherman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Matthew Kowgier

41 papers receiving 1.9k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons

2013 547 citations Andrew Lim, Matthew Kowgier et al. SLEEP profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Kowgier Canada	18	656	622	526	469	289	44	1.9k
Hans Klose Germany	29	157 0.2×	89 0.1×	119 0.2×	83 0.2×	253 0.9×	113	2.7k
Pascal Perney France	20	706 1.1×	612 1.0×	82 0.2×	83 0.2×	133 0.5×	80	1.4k
Kathleen F. Villa United States	21	247 0.4×	14 0.0×	276 0.5×	278 0.6×	174 0.6×	60	1.4k
Jesús Pujol Salud Spain	18	248 0.4×	123 0.2×	283 0.5×	58 0.1×	104 0.4×	57	1.3k
Warren May United States	27	220 0.3×	63 0.1×	187 0.4×	40 0.1×	247 0.9×	89	2.5k
Tatsuo Kagimura Japan	19	368 0.6×	17 0.0×	295 0.6×	126 0.3×	180 0.6×	79	1.2k
Martin Mücke Germany	20	144 0.2×	70 0.1×	161 0.3×	67 0.1×	347 1.2×	82	1.7k
Julie Davidson United Kingdom	14	298 0.5×	45 0.1×	264 0.5×	148 0.3×	95 0.3×	17	1.1k
Katsuji Nishimura Japan	20	153 0.2×	86 0.1×	58 0.1×	83 0.2×	50 0.2×	98	1.2k
Huiyong Zheng United States	24	143 0.2×	17 0.0×	149 0.3×	282 0.6×	349 1.2×	55	2.2k

Countries citing papers authored by Matthew Kowgier

Since Specialization

Citations

This map shows the geographic impact of Matthew Kowgier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Kowgier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Kowgier more than expected).

Fields of papers citing papers by Matthew Kowgier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Kowgier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Kowgier. The network helps show where Matthew Kowgier may publish in the future.

Co-authorship network of co-authors of Matthew Kowgier

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Kowgier. A scholar is included among the top collaborators of Matthew Kowgier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Kowgier. Matthew Kowgier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Westin, Shannon N., Kathleen N. Moore, Hye Sook Chon, et al.. (2025). Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation. International Journal of Gynecological Cancer. 35(2). 101703–101703.

Moore, Kathleen N., Shannon N. Westin, Hye Sook Chon, et al.. (2025). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation. Gynecologic Oncology. 200. 345–346. 1 indexed citations

Baurain, Jean‐François, Hye Sook Chon, Michael J. Sundborg, et al.. (2024). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial. Gynecologic Oncology. 190. S62–S63.

Blank, Stephanie V., Charles Anderson, Kathryn P. Pennington, et al.. (2024). 732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E. Annals of Oncology. 35. S557–S557. 1 indexed citations

Kowgier, Matthew, et al.. (2020). COMORBIDITY AND NON-PROSTHETIC INPATIENT REHABILITATION OUTCOMES AFTER DYSVASCULAR LOWER EXTREMITY AMPUTATION. SHILAP Revista de lepidopterología. 3(1). 33916–33916. 3 indexed citations

Biondi, Mia J., David Smookler, Stephen Perusini, et al.. (2019). Hepatitis C Core-Antigen Testing from Dried Blood Spots. Viruses. 11(9). 830–830. 20 indexed citations

Wong, William, Beate Sander, Chaim M. Bell, et al.. (2018). Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clinical Gastroenterology and Hepatology. 17(9). 1840–1849.e16. 76 indexed citations

Haddad, Robert I., Deborah J. Wong, Ye Guo, et al.. (2018). IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 29. viii397–viii397. 17 indexed citations

Maan, Raoel, Jagpal S. Klair, Orlando Cerocchi, et al.. (2017). The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir‐based regimens. Alimentary Pharmacology & Therapeutics. 46(1). 46–55. 13 indexed citations

10.

Alosaimi, Fahad D., et al.. (2017). Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis. Patient Preference and Adherence. Volume 11. 513–518. 10 indexed citations

11.

Sharma, Suraj, Matthew Kowgier, Bettina E. Hansen, et al.. (2017). Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. Journal of Hepatology. 68(1). 92–99. 147 indexed citations

12.

Sockalingam, Sanjeev, Raed Hawa, Susan Wnuk, et al.. (2017). Psychosocial predictors of quality of life and weight loss two years after bariatric surgery: Results from the Toronto Bari-PSYCH study. General Hospital Psychiatry. 47. 7–13. 37 indexed citations

13.

Lim, Andrew, Lei Yu, Matthew Kowgier, et al.. (2013). Modification of the Relationship of the Apolipoprotein E ε4 Allele to the Risk of Alzheimer Disease and Neurofibrillary Tangle Density by Sleep. JAMA Neurology. 70(12). 1544–1544. 203 indexed citations

14.

Lim, Andrew, Matthew Kowgier, Lei Yu, Aron S. Buchman, & David A. Bennett. (2013). Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. SLEEP. 36(7). 1027–1032. 547 indexed citations breakdown →

15.

Patel, Sanjay R., Robert Goodloe, Matthew Kowgier, et al.. (2012). Association of Genetic Loci with Sleep Apnea in European Americans and African-Americans: The Candidate Gene Association Resource (CARe). PLoS ONE. 7(11). e48836–e48836. 42 indexed citations

16.

Naglie, Gary, David B. Hogan, Murray Krahn, et al.. (2010). Predictors of Patient Self-Ratings of Quality of Life in Alzheimer Disease: Cross-Sectional Results From the Canadian Alzheimer's Disease Quality of Life Study. American Journal of Geriatric Psychiatry. 19(10). 881–890. 48 indexed citations

17.

Naglie, Gary, David B. Hogan, Murray Krahn, et al.. (2010). Predictors of Family Caregiver Ratings of Patient Quality of Life in Alzheimer Disease: Cross-Sectional Results from the Canadian Alzheimer's Disease Quality of Life Study. American Journal of Geriatric Psychiatry. 19(10). 891–901. 42 indexed citations

18.

Alibhai, Shabbir M.H., Marc Leach, Vikas Gupta, et al.. (2007). The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Critical Reviews in Oncology/Hematology. 64(1). 19–30. 55 indexed citations

19.

Willan, Andrew R. & Matthew Kowgier. (2007). Cost‐effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate. Health Economics. 17(7). 777–791. 15 indexed citations

20.

Leach, Marc, Matthew Kowgier, Ami Schattner, et al.. (2006). Quality of life (QOL) of older adults with acute myeloid leukemia (AML): Effects of treatment and time. Journal of Clinical Oncology. 24(18_suppl). 6566–6566. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact